Skip Nav Destination
Issues
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
Lucie Van Emmenis; Sheng-Yu Ku; Kaitlyn Gayvert; Jonathan R. Branch; Nicholas J. Brady; Subhasree Basu; Michael Russell; Joanna Cyrta; Aram Vosoughi; Verena Sailer; Hussein Alnajar; Etienne Dardenne; Elena Koumis; Loredana Puca; Brian D. Robinson; Michael D. Feldkamp; Annmarie Winkis; Nathan Majewski; Brent Rupnow; Marco M. Gottardis; Olivier Elemento; Mark A. Rubin; Himisha Beltran; David S. Rickman
Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Shaoxian Wu; Hao Huang; Runzi Sun; David Shihong Gao; Fan Ye; Jianing Huang; Ella Li; Andrew Ni; Kevin GuoKai Lu; Kong Chen; Jingting Jiang; Penelope A. Morel; Ziyang Zhong; Binfeng Lu
Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Brian J. Francica; Anja Holtz; Justine Lopez; David Freund; Austin Chen; Dingzhi Wang; David Powell; Franciele Kipper; Dipak Panigrahy; Raymond N. Dubois; Chan C. Whiting; Peppi Prasit; Thomas W. Dubensky
MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids
Oliver J. Pickles; Kasun Wanigasooriya; Anetta Ptasinska; Akshay J. Patel; Helen L. Robbins; Claire Bryer; Celina M. Whalley; Louise Tee; Neeraj Lal; Claudia M.A. Pinna; Nahla Elzefzafy; Philippe Taniere; Andrew D. Beggs; Gary M. Middleton
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Myrto Moutafi; Georgia-Angeliki Koliou; George Papaxoinis; Panagiota Economopoulou; Ioannis Kotsantis; Maria Gkotzamanidou; Maria Anastasiou; Dimitrios Pectasides; Efthymios Kyrodimos; Alexander Delides; Evangelos Giotakis; Nikolaos G. Papadimitriou; Ioannis G. Panayiotides; Christos Perisanidis; Aileen I. Fernandez; Vasiliki Xirou; Christos Poulios; Eleni Gagari; Vesal Yaghoobi; Niki Gavrielatou; Saba Shafi; Thazin Nwe Aung; Andromachi Kougioumtzopoulou; Vassilis Kouloulias; Konstantinos Palialexis; Stavros Gkolfinopoulos; Areti Strati; Evi Lianidou; George Fountzilas; David L. Rimm; Periklis G. Foukas; Amanda Psyrri
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
Junkai Wang; Alexander B. Saltzman; Eric J. Jaehnig; Jonathan T. Lei; Anna Malovannaya; Matthew V. Holt; Meggie N. Young; Mothaffar F. Rimawi; Foluso O. Ademuyiwa; Meenakshi Anurag; Beom-Jun Kim; Matthew J. Ellis
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Sapna Yadavilli; Jeremy D. Waight; Sara Brett; Meixia Bi; Tianqian Zhang; Yao-Bin Liu; Catherine Ellis; David C. Turner; Ashleigh Hahn; Hong Shi; Laura Seestaller-Wehr; Junping Jing; Qing Xie; Jafar Sadik Shaik; Xiao Ji; Robert Gagnon; William Fieles; Laura Hook; Steven Grant; Stephanie Hopley; M. Phillip DeYoung; Christina Blackwell; Michael Chisamore; Robert Biddlecombe; David J. Figueroa; Christopher B. Hopson; Roopa Srinivasan; James Smothers; Michele Maio; Danny Rischin; Daniel Olive; Elaine Paul; Patrick A. Mayes; Axel Hoos; Marc Ballas
LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Inyoung Lee; Miriam Doepner; Jillian Weissenrieder; Ariana D. Majer; Sophia Mercado; Angela Estell; Christopher A. Natale; Pamela J. Sung; J. Kevin Foskett; Martin P. Carroll; Todd W. Ridky
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
Vina P. Nguyen; Katie M. Campbell; Theodore S. Nowicki; Nila Elumalai; Egmidio Medina; Ignacio Baselga-Carretero; Maggie L. DiNome; Helena R. Chang; Denise K. Oseguera; Antoni Ribas; John A. Glaspy
A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
Michael A. Carducci; Ding Wang; Christina Habermehl; Matthias Bödding; Felix Rohdich; Floriane Lignet; Klaus Duecker; Oleksandr Karpenko; Linda Pudelko; Claude Gimmi; Patricia LoRusso
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Josep Tabernero; Philippe L. Bedard; Yung-Jue Bang; Maria Vieito; Min-Hee Ryu; Nathalie Fagniez; Mustapha Chadjaa; Christine Soufflet; Nina Masson; Anas Gazzah
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
H. Catherine Wilbur; Jennifer N. Durham; Su Jin Lim; Katrina Purtell; Katherine M. Bever; Daniel A. Laheru; Ana De Jesus-Acosta; Nilofer S. Azad; Bradley Wilt; Luis A. Diaz; Dung T. Le; Hao Wang
Correction: The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways
Marco Magistri; Lanie E. Happ; Jeremy Ramdial; XiaoQing Lu; Vasileios Stathias; Kranthi Kunkalla; Nitin Agarwal; Xiaoyu Jiang; Stephan C. Schürer; Sander R. Dubovy; Jennifer R. Chapman; Francisco Vega; Sandeep Dave; Izidore S. Lossos
Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression
Anna Besschetnova; Wanting Han; Mingyu Liu; Yanfei Gao; Muqing Li; Zifeng Wang; Maryam Labaf; Susan Patalano; Kavita Venkataramani; Rachel E. Muriph; Jill A. Macoska; Kellee R. Siegfried; Jason Evans; Steven P. Balk; Shuai Gao; Dong Han; Changmeng Cai
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds